Novabay Pharmaceuticals Inc Price/Book
What is the Price/Book of Novabay Pharmaceuticals Inc?
The Price/Book of Novabay Pharmaceuticals Inc is 0.98
What is the definition of Price/Book?
Price to book ratio represents the ratio between a company’s stock value and the book value per share.
mrq (most recent quarter)
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book of companies in the Health Care sector on NYSEMKT compared to Novabay Pharmaceuticals Inc
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Companies with price/book similar to Novabay Pharmaceuticals Inc
- Kubota has Price/Book of 0.98
- China Leasing has Price/Book of 0.98
- Worldwide Healthcare Trust Plc has Price/Book of 0.98
- Jaguar Health Inc has Price/Book of 0.98
- Manulife Floating Rate Senior Loan Fund has Price/Book of 0.98
- Broadstone Net Lease has Price/Book of 0.98
- Novabay Pharmaceuticals Inc has Price/Book of 0.98
- Cinevista has Price/Book of 0.98
- Alpha & Omega Semiconductor Ltd has Price/Book of 0.98
- abrdn Life Sciences Investors has Price/Book of 0.98
- Nile has Price/Book of 0.98
- Bénéteau SA has Price/Book of 0.98
- Green Brick Partners has Price/Book of 0.98